他汀类药物结合沙库巴曲缬沙坦对冠心病患者的效果OA

Objective:To analyze the results of statins combined with sacubitril valsartan in patients with coronary heart disease(CHD).Method:A total of 89 CHD patients admitted to the Affiliated Hospital of Putian University from June 2022 to July 2023 were selected as the study objects,and were divided into the reference group(44 cases)and the study group(45 cases)according to random number table method.Patients in the reference group were treated with statins,and patients in the study group were treated with sakubactril and valsartan on the basis of the above.Blood lipid index,inflammatory factor index,vascular endothelial function and hardness of the two groups were analyzed.Result:Before treatment,there was no significant difference in blood lipid indexes between the two groups(P>0.05).After treatment,the indexes of total cholesterol(TC),triglyceride(TG)and low-density lipoprotein(LDL-C)in the study group were significantly lower than those in the reference group,and high density lipoprotein(HDL-C)was significantly higher than that in the reference group,with statistical significance(P<0.05).Before treatment,there was no significant difference in inflammatory factors between the two groups(P>0.05).After treatment,the inflammation indexes in the study group were significantly lower than those in the reference group,and the difference was statistically significant(P>0.05).After treatment,the inflammation indexes in the study group were significantly lower than those in the reference group,and the difference was statistically significant(P<0.05).Before treatment,there was no significant difference in vascular endothelial function and hardness between the two groups(P>0.05).After treatment,the index of brachial artery endothelium-dependent diastolic function(FMD)in the study group was significantly higher than that in the reference group,and endothelin-1(ET-1)was significantly lower than that in the reference group,with statistical significance(P<0.05).Conclusion:The treatment of CHD with statin combined with sacubactril and valsartan is of high value,which can not only regulate blood lipid levels,but also effectively reduce inflammatory indicators and improve vascular endothelial function.